European experts advise against epilepsy drug in pregnancy

February 9, 2018
France's medicines regulator, known by the acronym ANSM, asked the London-based European Medicines Agency (EMA) to conduct a risk review of an epilepsy drug when used during pregnancy

An expert committee of Europe's medicines watchdog recommended Friday that a drug used to treat epilepsy and linked to malformations in children not be used in pregnancy.

The compound, valproate, is also used for migraine and , and doctors already advised against prescribing the for pregnant women in France.

France's medicines regulator, known by the acronym ANSM, asked the London-based European Medicines Agency (EMA) to conduct a risk review.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) said in a statement Friday it was recommending that valproate not be used by for any of the three medical conditions.

For women suffering from epilepsy, however, it may be impossible for some to stop after becoming pregnant, it said. These may have to continue treatment, though with "appropriate specialist care".

The experts also advised against prescribing the drug for "from the time they become able to have children", unless using contraception.

Valproate medicines are licenced under different names by national drugs authorities.

The committee recommendations will now go to another body of the EMA, which deals with concerns over drugs that are not centrally authorised in the EU.

Last April, a preliminary study showed that valproate caused "severe malformations" in as many as 4,100 children in France since the drug was first marketed in the country in 1967.

Women who took the during pregnancy to treat epilepsy were four times more likely to give birth to babies with , said a report of the French National Agency for the Safety of Medicines (ANSM) and the national health insurance administration.

Birth defects included spina bifida—a condition in which the spinal cord does not form properly and can protrude through the skin—as well as defects of the heart and genital organs.

The risk of autism and developmental problems was also found to be higher.

Explore further: Epilepsy drug behind up to 4,100 'severe birth defects' in France

Related Stories

Epilepsy drug behind up to 4,100 'severe birth defects' in France

April 20, 2017
The epilepsy medication valproate is responsible for "severe malformations" in 2,150 to 4,100 children in France since the drug was first marketed in the country in 1967, according to a preliminary study by French health ...

450 cases of birth defects from anti-epilepsy drug in France: health officials

February 23, 2016
A common drug used to treat epilepsy has caused congenital defects in around 450 babies in France who were exposed to the medication before birth in the uterus, according to an estimate by health authorities published Tuesday.

FDA warns pregnant women about migraine drugs

May 6, 2013
(HealthDay)—Pregnant women who struggle with migraine headaches should never use medicines containing the ingredient valproate because they can lower the IQ scores of their children, the U.S. Food and Drug Administration ...

Epilepsy drug dosage linked to specific birth defects

August 25, 2013
In a world first, new Australian medical research has given pregnant women with epilepsy new hope of reducing their chance of having a baby with physical birth defects.

Prescriptions for valproate not decreasing despite birth defect-causing concerns

July 24, 2013
A recent study shows that prescriptions for the antiepileptic drug valproate have not decreased in recent years even though the drug is known to cause severe birth defects and brain damage. A new study indicates that women ...

Recommended for you

Scientists identify new genetic causes linked to abnormal pregnancies and miscarriages

November 20, 2018
A team of scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University have identified three genes responsible for recurrent molar pregnancies, a rare complication that occurs ...

RNAi therapy mitigates preeclampsia symptoms

November 19, 2018
A collaboration of scientists from the University of Massachusetts Medical School, Beth Israel Deaconess Medical Center and Western Sydney University, have shown that an innovative new type of therapy using small interfering ...

New blood test detects early stage ovarian cancer

November 19, 2018
Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer—a disease which kills over 1000 Australian women and 150,000 globally each ...

Human Cell Atlas study reveals maternal immune system modifications in early pregnancy

November 14, 2018
The first Human Cell Atlas study of early pregnancy in humans has shown how the function of the maternal immune system is affected by cells from the developing placenta. Researchers from the Wellcome Sanger Institute, Newcastle ...

Soy formula feeding during infancy associated with severe menstrual pain in adulthood

November 9, 2018
New research suggests that infant girls fed soy formula are more likely to develop severe menstrual pain as young adults. The finding adds to the growing body of literature that suggests exposure to soy formula during early ...

A major role for a small organ in the immune response during pregnancy

November 9, 2018
The immune system of a pregnant woman is altered during pregnancy, but not in the way previously believed, according to results from a study at Linköping University, Sweden. This study, published in the Journal of Allergy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.